Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) EPS (Weighted Average and Diluted) (2016 - 2025)

Lipocine's EPS (Weighted Average and Diluted) history spans 13 years, with the latest figure at -$0.59 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) fell 34.09% year-over-year to -$0.59; the TTM value through Sep 2025 reached -$1.79, down 135.53%, while the annual FY2024 figure was -$0.0, 99.95% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.59 in Q3 2025 per LPCN's latest filing, down from -$0.41 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.66 in Q1 2024 to a low of -$1.27 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.29, with a median of -$0.41 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 333.33% in 2021, then tumbled 1800.0% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.14 in 2021, then crashed by 407.14% to -$0.43 in 2022, then rose by 2.33% to -$0.42 in 2023, then skyrocketed by 178.09% to $0.33 in 2024, then plummeted by 279.88% to -$0.59 in 2025.
  • Per Business Quant, the three most recent readings for LPCN's EPS (Weighted Average and Diluted) are -$0.59 (Q3 2025), -$0.41 (Q2 2025), and -$0.35 (Q1 2025).